Schmulson M, Dávalos M F, Berumen J
Laboratorio de Hígado, Páncreas y Motilidad (HIPAM), Unidad de Investigación en Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Hospital General de México Dr. Eduardo Liceaga, Ciudad de México, México.
Laboratorio de Hígado, Páncreas y Motilidad (HIPAM), Unidad de Investigación en Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Hospital General de México Dr. Eduardo Liceaga, Ciudad de México, México.
Rev Gastroenterol Mex (Engl Ed). 2020 Jul-Sep;85(3):282-287. doi: 10.1016/j.rgmx.2020.04.001. Epub 2020 Apr 15.
There is an increasing number of reports on the presentation of gastrointestinal symptoms in cases of COVID-19.
To review the studies reporting gastrointestinal symptoms in COVID-19.
Fifteen articles (2,800 patients) were identified. Gastrointestinal symptom frequency varied from 3.0% to 39.6% and included diarrhea (7.5%), náusea (4.5%), anorexia (4.4%), vomiting (1.3%), abdominal pain (0.5%), and belching/reflux (0.3%). Those symptoms can be the first manifestation of COVID-19, but whether they reflect a better or worse prognosis, is controversial. The potential relation of the angiotensin converting enzyme 2 receptor in the digestive tract as an entry route for the virus is discussed.
Gastrointestinal symptoms may be common in COVID-19, in some cases appearing as the first manifestation, even before fever and respiratory symptoms. Therefore, clinicians and gastroenterologists must be aware of those atypical cases during the current pandemic, as well as of the fecal-oral route and corresponding preventive measures.
关于新型冠状病毒肺炎（COVID-19）病例出现胃肠道症状的报道越来越多。
综述有关COVID-19胃肠道症状的研究。
共纳入15篇文章（2800例患者）。胃肠道症状发生率从3.0%到39.6%不等，包括腹泻（7.5%）、恶心（4.5%）、厌食（4.4%）、呕吐（1.3%）、腹痛（0.5%）和嗳气/反流（0.3%）。这些症状可能是COVID-19的首发表现，但它们是否预示着更好或更差的预后，仍存在争议。文中讨论了消化道中血管紧张素转换酶2受体作为病毒进入途径的潜在关系。
胃肠道症状在COVID-19中可能很常见，在某些情况下甚至在发热和呼吸道症状之前就作为首发表现出现。因此，在当前疫情期间，临床医生和胃肠病学家必须意识到这些非典型病例，以及粪-口传播途径和相应的预防措施。
